We report a unique, previously undescribed multigeneration kindred with von Hippel-Lindau (VHL) disease in whom clinical or genetic screening led to the detection of surgically resectable neoplastic disease in several family members.
Objective
We report a unique, previously undescribed multigeneration kindred with von Hippel-Lindau (VHL) disease in whom clinical or genetic screening led to the detection of surgically resectable neoplastic disease in several family members.
Summary Background Data
Patients with VHL disease have a propensity to develop neoplasms of several different organ sites. Retinal angiomas, cerebellar and spinal hemangioblastomas, solid organ cysts, and renal carcinoma are common lesions; pheochromocytomas and pancreatic islet cell tumors occur less frequently but are important causes of morbidity and mortality.
Methods
A detailed pedigree was constructed based on clinical screening and family history that describes the development of pancreatic islet cell tumors in four of five female siblings. VHL mutation analysis was performed in an attempt to determine if genotype-phenotype correlations could be made in this interesting family.
Results
The age of onset of VHL-associated neoplasms for three affected siblings was in the third decade of life and in the fourth decade for the fourth sibling. The mother of the four siblings affected with pancreatic tumors developed bilateral pheochromocytomas in the seventh decade of life; she has no pancreatic or kidney tumors. We identified maternal transmission of a missense mutation in codon 238 in exon 3 of the VHL gene in the four affected siblings with pancreatic islet cell tumors. Mutation screening on unaffected family members showed no abnormalities in the VHL gene. Interestingly, one of the four affected siblings had no evidence of VHL on her initial clinical screening evaluation; however, she was followed closely because of her mutated VHL gene. Four years after initial screening, she developed two pancreatic islet cell tumors 
METHODS Von Hippel-Lindau Screening
After presentation of the index case from this family, a detailed family history was obtained from other family members. The clinical diagnosis of VHL disease was based on established criteria.4"7'8 All living first-and second-degree family members were contacted; they underwent ophthalmologic evaluation, magnetic resonance imaging (MRI) of the brain and spinal cord, and abdominal ultrasound examination. Family members diagnosed with VHL disease underwent computed tomography (CT) of the abdomen and pelvis. The three most recent generations of the family were born in a single small town; hospital and autopsy reports were available on three of the five deceased persons.
A complete serum pancreatic profile (pancreatic oncofetal antigen, vasoactive intestinal peptide, pancreatic polypeptide, somatostatin, neurotensin, C-peptide, glucagon, gastrin, amylase, and glucose) was obtained for all affected family members. Serum parathyroid hormone, prolactin, calcium, cortisol, adrenocorticotropic hormone, calcitonin, and serum and urine catecholamine levels were also measured.
Mutation Screening
Blood samples from family members were subjected to VHL mutation analysis regardless of whether they had clinical evidence of VHL disease. The four siblings who underwent surgery for pancreatic islet cell tumors and their mother, who underwent bilateral adrenalectomy for pheochromocytomas, had tumor tissue samples subjected to genetic analysis. Two family members who had no clinical evidence of VHL provided blood samples for mutation analysis.
DNA was isolated from peripheral lymphocytes of persons from the affected kindred using a high salt technique.19 Primers corresponding to each of the three exons of the VHL gene were manufactured by Genosys (Genosys Biotechnologies, The Woodlands, TX). Polymerase chain reaction (PCR) amplification was carried out according to published conditions.20 Amplification products were electrophoresed in a 2% NuSieve (FML Corp., Rockland, ME) low-melting-point agarose gel. Bands corresponding to each amplified exon were cut from the gel and purified with the Qiagen PCR Prep Kit (Qiagen Inc., Chatsworth, CA). Sequencing was then performed using the Delta Taq Cycle Sequencing Kit (U.S. Biologicals, Cleveland, OH). Reaction products were analyzed on a 6% denaturing acrylamide gel.
Initially, PCR products were examined by single-strand conformation analysis to identify exons with mutations. This was accomplished by incorporating a32P dCTP during PCR amplification, denaturing the PCR amplicons, and then performing electrophoretic separation on a 6% nondenaturing MDE Hydrolink (J.T. Baker Co., Phillipsburg, NJ) acrylamide gel. After electrophoresis, the acrylamide gels were exposed to autoradiography film for 24 to 72 hours. To identify specific mutations, sequencing of exons was performed.
RESULTS

Family Description
The proband at age 29 years presented to an ophthalmologist complaining of blurred vision in the right eye. Retinal examination revealed bilateral retinal angiomas. MRI of the brain and spinal cord revealed a midline cerebellar vascular tumor consistent with a hemangioblastoma. Three months later, the patient presented with a 1-week history of abdominal pain. Abdominal CT revealed a 5-cm pancreatic head mass. Cytologic analysis of a fineneedle aspiration specimen was consistent with islet cell neoplasm. The patient had no symptoms or signs of an endocrine syndrome, there were no abnormal values on serum pancreatic and endocrine tests, and serum and urinary catecholamine levels were normal. There was no evidence of metastatic disease on the preoperative screening evaluation, but at laparotomy multiple 1-to 2- Because the second sibling had a point mutation in the VHL gene identical to her three younger sisters, she was followed annually with an eye examination, MRI of the spine and head, and CT of the abdomen and pelvis. Four years after her initial screening evaluation, CT revealed two hypervascular pancreatic head tumors <1 cm in diameter, a complex left renal cyst, and enlarged bilateral ovarian cysts. Serum and urine laboratory tests were normal. A pancreaticoduodenectomy and left heminephrectomy was performed, revealing two <1-cm islet cell tumors and a complex renal cyst with severe cellular atypia but no invasive malignancy. There was no evidence of metastatic foci of islet cell malignancy.
The two sisters who had unresectable primary pancreatic tumors and liver metastases were treated on protocol with external beam irradiation to the pancreas followed by systemic chemotherapy with 5- In constructing the VHL pedigree, we inferred that the maternal grandmother of the proband was the initiating case ( Fig. 1) The elder female sibling of the proband's mother died at age 1 year from pneumonia. The immediate younger female sibling died suddenly at age 51 years; autopsy showed hemorrhage into a large cerebellar hemangioblastoma (see Fig. 1 ). Two of the five children of this latter woman are affected by VHL. The elder female child died suddenly at age 25 years from hemorrhage into a cerebellar hemangioblastoma. The younger female has only bilateral retinal angiomas and multiple pancreatic cysts. The final living four siblings of the proband's mother and their children and grandchildren have no clinical or radiographic evidence of VHL.
VHL Mutation Screening
Single-strand conformation analysis of the VHL gene in this pedigree identified an aberrantly migrating band in affected persons in exon 3 (Fig. 2) 
